Ergomed PLC
F:2EM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
E
|
Ergomed PLC
F:2EM
|
UK |
|
Prologue SA
F:69P
|
FR |
|
Daio Paper Corp
F:DPR
|
JP |
|
Nitto Denko Corp
F:ND5
|
JP |
|
Maruha Nichiro Corp
F:6MN
|
JP |
|
D
|
Daishin Securities Co Ltd
KRX:003545
|
KR |
|
Energeia AS
F:F620
|
NO |
|
E
|
Element Nutritional Sciences Inc
F:93X
|
CA |
|
Kuangchi Science Ltd
F:92N0
|
HK |
|
Gunze Ltd
F:GUN
|
JP |
|
F
|
Founder Holdings Ltd
XMUN:FOU1
|
HK |
|
Ovzon AB (publ)
F:OVZ
|
SE |
|
Galileo Resources PLC
F:2GA
|
UK |
|
LAVA Therapeutics NV
F:4PKB
|
NL |
|
Almawave SpA
F:101
|
IT |
|
Nitto Denko Corp
F:ND50
|
JP |
|
S
|
Sihuan Pharmaceutical Holdings Group Ltd
OTC:SHPHF
|
CN |
|
Hysan Development Co Ltd
F:HYN
|
HK |
|
H
|
Hysan Development Co Ltd
XMUN:HYN
|
HK |
|
Noble Helium Ltd
F:GN1
|
AU |
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is 2EM's stock price target?
Not Available
2EM does not have any price targets made by Wall Street professionals.
What is the Revenue forecast for Ergomed PLC?
Projected CAGR
11%
Over the last 10 years, the compound annual growth rate for Revenue has been 26%. The projected CAGR for the next 3 years is 11%.
What is the Operating Income forecast for Ergomed PLC?
Projected CAGR
22%
Over the last 10 years, the compound annual growth rate for Operating Income has been 46%. The projected CAGR for the next 3 years is 22%.